FDA approves daraxonrasib

The FDA, the agency that regulates drugs in the United States, has approved daraxonrasib (Rasonque) for certain adults with metastatic pancreatic adenocarcinoma. The new treatment also stands out for the target it aims to hit: proteins in the RAS family, which are involved in the biology of the vast majority of pancreatic ductal adenocarcinomas.

The approval, announced on August 26, 2026, was based primarily on RASolute 302, a phase 3 trial published in the New England Journal of Medicine. The trial specifically evaluated 500 patients with metastatic pancreatic ductal adenocarcinoma, the most common subtype of pancreatic adenocarcinoma, who had already received systemic treatment.

In the overall study population, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. The median time to disease progression or death was also longer: 7.2 months versus 3.6 months, respectively.

The median is a population-level measure. Therefore, the difference between the two groups does not mean that each patient treated with daraxonrasib gained 6.5 months of life.

Why RAS matters in pancreatic cancer

RAS proteins take part in signals that regulate processes such as cell growth and survival. Alterations that keep this signaling inappropriately active can favor the maintenance and growth of the tumor.

In pancreatic ductal adenocarcinoma, oncogenic mutations in the RAS family are present in more than 90% of tumors, according to the study published in the New England Journal of Medicine.

This is the mechanism daraxonrasib seeks to interfere with. The drug is an oral multi-selective inhibitor of RAS(ON) — the active state of the protein — and was designed to hit multiple forms of RAS rather than a single variant.

This does not mean that all molecular alterations respond to treatment in the same way. In RASolute 302, 91.8% of participants had RAS G12 mutations. In this group, median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy; median progression-free survival was 7.3 and 3.5 months, respectively.

What the study showed

RASolute 302 was an international, multicenter, randomized, open-label trial. Of the 500 participants, 248 received daraxonrasib and 252 received protocol-specified chemotherapy selected by the investigator.

In the overall population, the hazard ratio for death was 0.40 and, for disease progression or death, 0.49, both favoring daraxonrasib. These measures compare the occurrence of events between the groups over the course of follow-up and should not be interpreted as an individual patient’s probability of dying.

The study was funded by Revolution Medicines, the company responsible for developing the drug.

Which patients the treatment was approved for

The indication granted by the FDA needs to be distinguished from the specific population studied in RASolute 302.

The FDA authorized daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic treatment.

The pivotal trial, in turn, evaluated patients with metastatic pancreatic ductal adenocarcinoma whose disease had progressed after one prior line of systemic therapy.

There is, therefore, a difference between the study population and the full population covered by the regulatory indication. The results of RASolute 302 should not be automatically extrapolated to localized disease, treatment after surgery, other types of pancreatic tumors or first-line treatment for all patients.

The new treatment does not replace surgery

This distinction is especially important when discussing the role of surgery.

Surgical oncologist Dr. Rodrigo Surjan emphasizes that daraxonrasib was studied in patients with advanced, metastatic disease, a different scenario from that of patients with a potentially resectable tumor.

According to him, whether surgery is possible depends on factors such as the presence of metastases and the tumor’s relationship to major blood vessels, including the portal vein, the superior mesenteric vein and artery, the hepatic artery and the celiac trunk. These factors help define scenarios such as resectable, borderline resectable or locally advanced tumors and guide the treatment strategy.

In patients for whom resection is possible, surgery remains a central part of a potentially curative strategy.

For that reason, Surjan warns against an interpretation he considers inappropriate given the attention the new drug has received:

“Under no circumstances can we interpret this study as meaning that it’s no longer necessary to operate on pancreatic cancer. That wasn’t even tested.”

One question for future studies, according to the surgeon, is whether more effective systemic treatments might make some patients who are initially not surgical candidates operable, or increase the number of those who reach resection.

“These are data we don’t have yet, which will require many studies,” Surjan says.

A survival gain is not the same as a cure

Daraxonrasib showed a survival advantage over chemotherapy in the setting studied. That does not mean the trial demonstrated a cure for metastatic pancreatic cancer.

“We’re not talking about a cure,” Surjan stresses.

The distinction matters because results such as 13.2 months versus 6.7 months can be oversimplified outside the scientific setting. They represent medians observed in two groups in a clinical trial and do not make it possible to predict how long any given patient will live.

Adverse effects also weigh on the decision

Grade 3 or higher adverse events occurred in 61.8% of patients treated with daraxonrasib and in 69.6% of those who received chemotherapy. Treatment-related events leading to discontinuation were recorded in 1.2% and 11.2%, respectively.

Among the common adverse effects associated with daraxonrasib, the FDA lists rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage.

The numbers alone do not support the conclusion that daraxonrasib is overall safer than chemotherapy. The assessment also depends on the type, severity and duration of the toxicities and on the patient’s clinical condition.

Resistance is already being investigated

One of the questions surrounding the new therapy is how long RAS blockade can keep acting on the tumor.

A study published in August 2026 in Nature Medicine analyzed circulating tumor DNA from 44 patients treated with daraxonrasib in a phase 1/2 trial. Genomic alterations in RAS signaling that emerged during treatment were identified in 26 of them, or 59%, including amplifications of mutant KRAS and alterations involving other cell signaling pathways.

These data do not come from RASolute 302 and do not change the results of the phase 3 trial. They help investigate how some tumors may develop resistance and provide clues for future treatment strategies.

What still needs to be clarified

The approval answers an important question: in the population studied in RASolute 302, daraxonrasib showed a benefit compared with chemotherapy. But questions remain about which patients will benefit most, the best time to use the drug, the role of different molecular alterations and the mechanisms of resistance.

It will also be necessary to observe how it performs outside clinical trials, in a more heterogeneous population, and to investigate separately any potential use in other disease settings.

Among these questions is precisely the one raised by Surjan: could more effective systemic therapies, in the future, change the possibility of surgery for certain patients? The available data cannot yet answer that.

What about Brazil?

The August 26 approval was granted by the FDA and applies to the United States. It does not mean automatic authorization for sale in Brazil, which depends on the Brazilian regulatory process.

Daraxonrasib introduces a new treatment strategy for a specific and difficult setting in pancreatic cancer: attacking, in a multi-selective way, a family of proteins that for decades represented one of the great challenges in developing drugs against these tumors.

The results of RASolute 302 show that this strategy can produce meaningful clinical benefit in patients with previously treated metastatic disease. The next step will be to understand how far this benefit can go — which patients respond best, how to overcome resistance and whether RAS blockade could take on other roles in the treatment of pancreatic cancer.

_____

References

1. O’Reilly EM, Wainberg ZA, Hendifar AE, et al.; RASolute 302 Trial Investigators. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2026;395(4):325–337. Published online May 31, 2026.

https://doi.org/10.1056/NEJMoa2605555

2. U.S. Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. August 26, 2026.

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma

3. Revolution Medicines, Inc. RASONQUE (daraxonrasib) — Prescribing Information. Labeling approved by the U.S. Food and Drug Administration. 2026. Application 220910; Reference ID 5858723.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf

4. Aronchik I, Kar S, Zhuang Y, et al. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nature Medicine. Published August 11, 2026.

https://doi.org/10.1038/s41591-026-04537-w

5. ClinicalTrials.gov. Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). RASolute 302. Registration NCT06625320. Sponsor: Revolution Medicines, Inc.

https://clinicaltrials.gov/study/NCT06625320